Fabino Enterprises Ltd
Incorporated in 2011, Fabino Enterprises manufactures, markets, trades, and does packing of pharmaceutical and other wellness focused consumer products[1]
- Market Cap ₹ 4.27 Cr.
- Current Price ₹ 20.3
- High / Low ₹ 39.0 / 13.0
- Stock P/E
- Book Value ₹ 19.1
- Dividend Yield 0.00 %
- ROCE 5.61 %
- ROE 1.44 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 1.06 times its book value
- Company's working capital requirements have reduced from 212 days to 104 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Company has a low return on equity of 0.89% over last 3 years.
- Company has high debtors of 288 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|
| 3.36 | 21.01 | 17.98 | 20.41 | |
| 3.33 | 20.89 | 17.87 | 20.65 | |
| Operating Profit | 0.03 | 0.12 | 0.11 | -0.24 |
| OPM % | 0.89% | 0.57% | 0.61% | -1.18% |
| 0.02 | 0.01 | 0.29 | 0.46 | |
| Interest | 0.01 | 0.04 | 0.13 | 0.16 |
| Depreciation | 0.03 | 0.04 | 0.08 | 0.10 |
| Profit before tax | 0.01 | 0.05 | 0.19 | -0.04 |
| Tax % | 0.00% | 20.00% | 68.42% | |
| 0.01 | 0.04 | 0.06 | -0.16 | |
| EPS in Rs | 0.05 | 0.19 | 0.29 | -0.76 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 64% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -700% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -14% |
| 1 Year: | -23% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 1% |
| Last Year: | 1% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|
| Equity Capital | 2.10 | 2.10 | 2.10 | 2.10 |
| Reserves | 2.01 | 2.04 | 2.10 | 1.91 |
| 0.41 | 1.27 | 1.79 | 1.76 | |
| 0.50 | 9.95 | 11.67 | 9.53 | |
| Total Liabilities | 5.02 | 15.36 | 17.66 | 15.30 |
| 0.15 | 0.34 | 0.55 | 0.42 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| 4.87 | 15.02 | 17.11 | 14.88 | |
| Total Assets | 5.02 | 15.36 | 17.66 | 15.30 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| -0.68 | -0.77 | 0.12 | |
| -0.01 | -0.28 | -0.42 | |
| 0.34 | 0.86 | 0.48 | |
| Net Cash Flow | -0.35 | -0.18 | 0.18 |
| Free Cash Flow | -0.69 | -1.01 | -0.17 |
| CFO/OP | -2,233% | -633% | 227% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Debtor Days | 274.84 | 219.07 | 287.66 |
| Inventory Days | 147.24 | 24.21 | 26.56 |
| Days Payable | 45.78 | 179.31 | 252.78 |
| Cash Conversion Cycle | 376.29 | 63.97 | 61.44 |
| Working Capital Days | 444.30 | 86.34 | 104.14 |
| ROCE % | 1.81% | 5.61% |
Insights
In beta| Dec 2021 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Number of Permanent Employees Count ・Standalone data |
|
|||
| Trade Receivable Turnover Ratio x ・Standalone data |
||||
| Active Products (SKUs) Count ・Standalone data |
||||
| Capacity Utilization - Protein/Malt Powder % ・Standalone data |
||||
| Installed Capacity - Protein/Malt Powder Tonnes PA ・Standalone data |
||||
Extracted by Screener AI
Documents
Announcements
-
Public Announcement - Open Offer
3h - Aryaman Financial Services Ltd ("Manager to the Offer") has submitted to BSE a copy of Public Announcement under Regulations 3(1) and 4 read with Regulations …
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
11 Apr - Company confirms it is not a Large Corporate as of 31 March 2026; no FY27 disclosure required.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 11 Apr
- Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 10 Apr
-
Closure of Trading Window
24 Mar - Trading window closed from April 1, 2026 until 48 hours after audited FY2025-26 results announcement.
Business Overview:[1][2]
a) FEL is an ISO 9001:2015 pharmaceutical company located near the Delhi NCR region. It offers a wide range of allopathic and herbal products.
b) Company markets pharmaceutical formulation for domestic market and sells through own distribution network and sales force under
their own brand name
c) It gets Ayurvedic formulations manufactured through Loan Licensing facilities, Packing, Labelling etc.
d) Company exports wellness and FMCG products like Coffee, Malt powder, Protein powder, Hair shampoo which it also markets